🔥 Turbo-Stock

Invivyd's entire near-term thesis rides on DECLARATION, the Phase 3 pivotal trial for VYD2311 (a next-gen, longer-acting successor to its commercial antibody PEMGARDA) — enrollment completed in June 2026 and topline data is guided for approximately late Q3 2026, i.e. within days of today. The stock has been crushed heading into the readout: -66% YTD, with an 8% single-day drop on Sep 22 after a Q2 EPS/revenue miss, leaving almost no cushion if the trial disappoints. Cash of $160.1M (Q2 2026) is explicitly guided to cover through the DECLARATION readout and initial commercial launch readiness, so this is a binary data bet, not a survival one — but the beaten-down legacy franchise and imminent timing mean there's little room for error.

Capricor's Deramiocel BLA gets its second FDA swing on Nov 22, 2026 — the PDUFA date was pushed from Aug 22 after Capricor narrowed its DMD claim to upper-limb function only (PUL 2.0), the exact endpoint the Jul 29-30 adcomm was directionally supportive on even while voting 9-3 against the original, broader DMD-cardiomyopathy indication. The stock has already rallied from $4.19 (the day-after-adcomm low) back to ~$9.91, so some approval odds are priced in, but this is the same drug's second regulatory decision point after a Jul 2025 CRL — not a clean coin flip. Cash of ~$279M (Q1 2026) makes this a purely regulatory bet, not a survival one.

The prior report's Oct 7 'Q3 earnings' catalyst never happens as such — RZLV is a UK-domiciled foreign private issuer that files an H1 6-K and an annual 20-F, not US-style quarterly reports; TipRanks lists the next full financial report as ~Apr 29, 2027 (FY2026). The real events since the last report were the Sept 1, 2026 H1 6-K (revenue $130.8M, ~20x YoY, $360M FY26 guide reaffirmed) and the Sept 23 cost-cut announcement targeting $60M in annualized savings and positive adjusted EBITDA by H1 2027. ⚠️ SURVIVAL: the Sept 1 filing shows the going-concern working-capital deficit MORE THAN DOUBLED to $205.2M (from $87.1M in the Mar 2026 20-F) on a $139.5M H1 net loss, with accumulated deficit now $499.1M; cash was $100.5M as of Jun 30 against an active $39.9M ATM program and a just-completed $250M registered offering already diluting the share count. Roth Capital cut its target to $6.50 from $9.50 on the print — the market's read is net negative despite the 20x revenue beat. This stays in the turbo lane because the growth is independently verified and Oct 6, 2026's Investor Day is a genuine near-term proof point for the cost-cut plan, but the asymmetry has shifted materially toward the downside since Aug: scoreLabel downgraded from Moonshot to ค่าขนม, sizing cut to 2%.

Spire's bookings momentum has genuinely strengthened since the last report: $33.2M NOAA contract (Sep 22, with surge options to ~$66M), $28M NOAA hyperspectral microwave-sounding deal (Aug 26), €4M EUMETSAT renewal (Aug 25), and a $3.7M NOAA award (Aug 14) — over $65M in fresh bookings in six weeks. Q2 2026 earnings (Aug 12) showed $18.0M revenue (+16% YoY ex-Maritime, +19% sequentially), $91.7M cash with no debt, and FY26 guidance reaffirmed at $75-85M — but gross margin slipped to 34% on a WildFireSat contract cancellation, and the stock fell 17.8% despite the otherwise-strong bookings quarter. The Diehl Defence missile-tracking MOU — the real moonshot lever — has no confirmed progress update since the last report; it remains MOU-stage, not a signed contract. Cash position is healthy, removing near-term survival risk.

The IAI loitering-munitions partnership catalyst still hasn't converted into a Department of War contract three months after Northland flagged it (Jul 2026) — the stock is essentially flat ($5.33 → $5.28) despite the company adding three more partnerships since (FANUC America for manufacturing/logistics robots, NORDA Dynamics for terminal guidance, Orkid Tech for fixed-wing UAVs) and a Q2 print that beat revenue estimates (+470% YoY, +63% QoQ, backlog up to $24.6M from $17M). The market's muted +0.3% earnings-day reaction to that beat — on an EPS miss of -$0.27 vs -$0.24 est. — signals investors want profitability progress and/or the DoW contract specifically, not just partnership headlines. Consensus target is $10.75 (+103.6%), Northland's raised $15 (+184%) is still the high end and still short of a clean 200%+ floor without assuming a further re-rate. Thesis intact but unproven: partnership_win is a measured laggard catalyst type in this lane per skill-feedback (turbo tier2: n=16, medianExcessVsBenchPct -3.8pp vs +2pp overall, gap -5.8pp), so conviction here rests on the DoW-specific tail risk/reward, not the general cadence of partnership news. Position small — 2-5% max.

Mobilicom's H1 2026 print (Aug 13) confirmed the DoD Program of Record moved from episodic purchase orders to a monthly delivery cadence — a real structural inflection — and the company has since added an Israeli Tier-1 defense design win (Aug 5) and a follow-on Asia-Pacific robotics order (Sept 14). But H1 revenue grew only 19% YoY to $1.73M while net loss ballooned to $6.69M (from $0.07M in H1 2025) as opex surged to $9.31M — the market's read has been net negative, with the stock drifting from $5.14 to $4.63 (-9.9%) over the seven weeks since that report despite the design-win headlines. Cash fell to $15.08M (Jun 30) from $19.0M (Dec 2025); at the adjusted $591K/month burn that's ~25 months of runway, or ~18 months at the unadjusted $859K/month rate — both clear the 12-month survival bar and no active ATM was found in recent filings, so this is NOT a survival flag, but the burn trend needs to stabilize by Nov 12. catalystType is partnership_win, turbo's weakest bucket (medianExcessVsBenchPct -3.8pp vs +2.0pp lane overall, n=16) — position sized down to 2% (from the prior 3%) to reflect both that headwind and the widened losses, despite the real, converting DoD contract underneath a $60M market cap.

Archer cleared a major new catalyst since the last report: the antitrust waiting period on its acquisition of Boeing's Wisk Aero (autonomous eVTOL tech), Insitu (military drones) and SkyGrid (airspace management software) expired Sep 18, with the deal expected to close by end of 2026 pending other regulatory approvals. That materially expands the thesis beyond pure FAA Type Certification into defense-adjacent, autonomy-IP territory. Cash position is $1.56B as of Q2 2026 (Aug 10) against a $263.2M quarterly net loss — real burn (up from $217.7M last quarter) but still ~5-6 quarters of runway, well clear of any survival threshold. Cathie Wood's ARK bought shares this month, funded by selling PLTR and AMD. Phase 4 FAA certification itself has no fresh confirmed timeline update since the last report, and the stock remains rate-sensitive — it just sold off 7% on rising yields.

BTQ hit a real technical milestone since the last report — its QCIM core was validated in a TSMC 28nm silicon environment (Aug 7), a step beyond the design-completion news covered before, and the company reaffirmed a year-end 2026 target to ship test chips to customers. Commercial activity is genuinely broadening: an MOU with ITCENGLOBAL (a large Korean IT conglomerate), QSSN now powering Korea's first stablecoin pilot, a commercial pipeline described as ~16 organizations across five countries, and a new hire (ex-Samsung Knox security lead) to push commercialization. The problem is the balance sheet: cash fell further to CAD 9.73M at the Q2 print (from C$12.1M last report) against an active C$150M ATM program with no news of it being wound down — the survival risk flagged last report has deepened, not resolved, and the stock is down 30.6% as the market prices that in ahead of the operational progress.

Two genuinely concrete developments since the last report: the NRC formally docketed the KRONOS construction permit application for a University of Illinois site, with environmental review targeted for 2027 and construction expected mid-2027 — real dates where before there was only 'formal review activities' with no timeline. Second, a Sep 25 non-binding LOI with IP3 Corporation and Cybernetic Intelligence to jointly pursue nuclear-powered AI infrastructure taps directly into the hot AI-datacenter-power theme, a real expansion of the addressable narrative. Needham initiated coverage Sep 21 at Buy, $33 (the first fresh analyst signal since the last report), pulling the 8-analyst consensus to $37.57 (+135%) — still real upside but honestly still below this board's classic 200%+ turbo bar, unchanged from last report. Cash remains exceptional (~$580M), fully removing survival risk. This is a genuine progress update, not a fresh high-conviction pick.

IQM's commercial momentum has genuinely accelerated since the last report — a second full-stack system sale to Toyo (Japan, Sep 15), a first South American deployment via Brazil's Eldorado Research Institute (Sep 17), and a staged upgrade path selected by Finland's LUMI AI Factory toward logical qubits (Sep 10) — plus BTIG initiated coverage at Buy with a $20 target (~Sep 21), the first fresh sell-side validation since the IPO. Yet the stock fell on EVERY one of those three announcement days (-1.63%, -5.09%, -4.93%), the exact 'good news doesn't move this stock' pattern the last report flagged, now with three more data points confirming it's persistent rather than a one-off. Analyst coverage remains thin (2 analysts: BTIG Buy $20, Redburn Hold $12.88, average $16.44) — per this run's tier2 feedback, IQMX's catalystType (partnership_win) is a measured LAGGARD across the turbo lane (medianExcessVsBenchPct -3.8pp vs +2.0pp overall, n=16), which argues for keeping conviction and sizing small even as the underlying commercial story improves. Cash (€309.4M, runway into Q2 2028) removes survival risk.